A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy
Qiang Wang1, Fei Qi2, Xiaopeng Song3, Jie Di2, Licheng Zhang3, Yuan Zhou4, Xin Lu4, Jin Chang5, Yonghua Yu1
1 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan 250117, China
2 Department of Radiation Oncology, Laiwu Central Hospital, Xinwen Mining Group, Laiwu 271103, China
3 Department of Oncology, No. 88 Hospital of PLA, Shandong Province, Tai'an 271000, China
4 Department of Radiotherapy, Tai'an Cancer Hospital, Shandong Province, Tai'an 271000, China
5 Department of Oncology, Affiliated Hospital of Taishan Medical College, Shandong Province, Tai'an 271000, China
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jiyan Road 440, Jinan 250117
Source of Support: None, Conflict of Interest: None
Aim of Study: The survival rate in high-grade glioma (HGG) patients receiving a combined regimen of radiotherapy (RT) and temozolomide after tumor resection was increased. However, cognitive deficits and depression after the treatments challenge the treatments. The aim of this study was to evaluate the cognition and depression in postoperative patients with HGG following RT and chemotherapy.
Materials and Methods: Six-five eligible patients were included in the study. Cognition and depression were examined at baseline (after surgery before RT), every 3 months during follow-up using mini–mental state examination and Zung Self-Rating Depression Scale (SDS), respectively.
Results: Our results showed that cognition was not significantly affected after treatments (F = 1.19, P = 0.32). However, significant differences between baseline and follow-ups were found regarding SDS scores (F = 3.26, P =0.0.01). SDS score at the 3rd month was significantly higher than that at baseline (t = −3.16, P = 0.002).
Conclusion: This prospective study showed that although cognition was not significantly affected, the treatment caused depression, particularly at the 3rd month. These data implicated that interventions should be designed to deal with depression in the 3rd month.